Special Issue "Medicinal Chemistry and Pharmacological Activities of Heparin and Related Drugs"
Deadline for manuscript submissions: 25 December 2023 | Viewed by 5997
Interests: heparin mimetics; drug discovery; respiratory inflammatory disease; heparanase; SARS-CoV-2; glycosaminoglycan; extracellular matrix
In the last couple of years, there has been a resurgence of interest in heparin and related drugs. In part, this was fueled by the COVID-19 pandemic and the revelation that heparin and heparan sulfate can interact with the SARS-CoV-2 spike protein and inhibit SARS-CoV-2 infection in vitro. These findings came on the back of a greater appreciation that heparin has a wide range of activities that are not related to anti-coagulation, with its anti-inflammatory, anti-viral, and anti-cancer effects being particularly well known.
Until recently, capitalizing on heparin’s non-anticoagulant activities for the development of new drugs has been difficult because of limitations in technologies for the synthesis and structural analysis of these complex polysaccharides. However, years of work have led to methodologies that enable the performance of detailed structural analyses of natural heparin and heparan sulfate fragments, and of synthetic heparin mimetics. Coupled with this, better molecular modelling methodologies for understanding the structure–function interactions of both the natural fragments and the mimetics are under development. The adaptation of organic chemistry synthesis techniques to the production of heparin mimetics and the chemoenzymatic syntheses of heparin and heparin-like fragments means the stage is now set for an exploration of the chemical space occupied by these structures and their potential as drugs.
This Special Issue aims to highlight the excitement felt by many of us in this field at these developments. The journal Pharmaceuticals invites both reviews and original articles on the challenges and opportunities of developing heparin and heparin-inspired molecules for drugs targeting disease indications with inflammatory, viral or cancerous components. The collection of manuscripts will be published as a Special Issue entitled “Medicinal Chemistry and Pharmacological Activities of Heparin and Related Drugs”.
Prof. Dr. Deirdre R. Coombe
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- heparan sulfate mimic
- heparin mimetic
- sulfated polysaccharide drug